A new era for castrate resistant prostate cancer: a treatment review and update. - Wikidata - awgldk - TriplyDB

A new era for castrate resistant prostate cancer: a treatment review and update.

A new era for castrate resistant prostate cancer: a treatment review and update.

http://www.wikidata.org/entity/Q37985547

about

PSA and beyond: alternative prostate cancer biomarkers Micrornas in prostate cancer: an overview.MicroRNAs and epithelial-mesenchymal transition in prostate cancer.Novel tumor suppressor microRNA at frequently deleted chromosomal region 8p21 regulates epidermal growth factor receptor in prostate cancer.Adherence to abiraterone among the first 86 recipients after release in Saskatchewan.Bombesin-conjugated nanoparticles improve the cytotoxic efficacy of docetaxel against gastrin-releasing but androgen-independent prostate cancer.Potential use of chymotrypsin-like proteasomal activity as a biomarker for prostate cancer.

P2860

Q26770646-3C66FA64-205C-4203-9ECF-E1E05C9A5197 Q30234658-2FACA5F6-CD01-4790-9148-2A76F29C7980 Q37687205-6C675AC4-F16B-4378-849C-089C6C828EB5 Q37688542-44E1F215-E39C-49FE-9481-6ABD833DE986 Q38416196-6609E316-108D-4187-80A1-90E59E8B79AF Q38834893-8BD6987C-F436-4187-B259-D930A3F7268A Q52351127-473E8307-25ED-4F27-8559-D3FB5E9BCA65

P2860

A new era for castrate resistant prostate cancer: a treatment review and update.

http://www.wikidata.org/entity/Q37985547

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

A new era for castrate resistant prostate cancer: a treatment review and update.

@en

A new era for castrate resistant prostate cancer: a treatment review and update.

@nl

type

label

A new era for castrate resistant prostate cancer: a treatment review and update.

@en

A new era for castrate resistant prostate cancer: a treatment review and update.

@nl

prefLabel

A new era for castrate resistant prostate cancer: a treatment review and update.

@en

A new era for castrate resistant prostate cancer: a treatment review and update.

@nl

P1433

Q37985547-051A231A-A88D-4E73-B5CC-A23A07D958F0

P1476

Q37985547-31CEE9A6-BEA4-4493-9104-35FE7C4E083B

P2093

Q37985547-5310965C-FE8F-4468-8934-44C6FDBEFEDC

Q37985547-5603A564-C9E8-4F2A-94AE-D6022BF56A34

Q37985547-ED6067CF-9BBB-44C4-8DE5-2ACD0BC2603E

P2860

Q37985547-0160EA8B-F86B-4897-902B-98BCEAB19F07

Q37985547-10F1E1A4-A50B-49E1-9EAC-941FC613F738

Q37985547-11C1BFAA-6EC0-4CFD-A893-3B32B96AD794

Q37985547-27444B01-EE77-46AC-9048-13CEBA392CEF

Q37985547-280E88CC-7BD1-4C69-B42E-966F52B58DD7

Q37985547-2F2160BB-CDB3-422B-A361-20AAA16E7C9D

Q37985547-2F450D65-9AB2-422D-81D1-191C01191077

Q37985547-3EB6E5F2-D3DD-4A42-99CE-EA28EBB66517

Q37985547-403D7A8D-4FBF-40BF-BE7B-05D868938EE2

Q37985547-45467574-E483-4E2B-9476-74AF7D4AA42A

P304

Q37985547-CD8E6D09-9382-4AB2-A109-080B240DC459

P31

Q37985547-3E7D21E1-D5BB-4030-85E0-0C3A8A70A1A5

P356

Q37985547-8F2DC6A8-B69D-4233-91BA-02F2A9FDE470

P433

Q37985547-5B7EE1C8-818F-4581-A808-D96A33699B8B

P478

Q37985547-984C9928-66D0-4DA6-A009-7AE65A00CA2F

P577

Q37985547-44319053-371D-404B-B660-4E0D70FBCE6F

P698

Q37985547-5219772F-EE9A-46BA-A31A-522B56BA0684

P356

1078155212437599

P1433

Journal of Oncology Pharmacy Practice

P1476

A new era for castrate resistant prostate cancer: a treatment review and update.

@en

P2093

Anthony Jarkowski

http://www.w3.org/2001/XMLSchema#string

Mei Ka Fong

http://www.w3.org/2001/XMLSchema#string

Ryan Hare

http://www.w3.org/2001/XMLSchema#string

P2860

Sipuleucel-T immunotherapy for castration-resistant prostate cancer

Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

Abiraterone and increased survival in metastatic prostate cancer

Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial

Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer.

Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy.

Adverse effects of androgen deprivation therapy: defining the problem and promoting health among men with prostate cancer.

Selective blockade of androgenic steroid synthesis by novel lyase inhibitors as a therapeutic strategy for treating metastatic prostate cancer.

P304

343-354

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/1078155212437599

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

18

http://www.w3.org/2001/XMLSchema#string

P577

2012-02-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22343966

http://www.w3.org/2001/XMLSchema#string